Baxalta Now Part Of Shire

This study tested a gene therapy called BAX 888 in 4 adult men with severe hemophilia A, a bleeding disorder. Participants received a single intravenous infusion of the therapy to help their bodies produce a missing clotting protein. The main goals were to check for side effects …

This study tested a medicine called vonicog alfa (rVWF) to control bleeding in 47 children under 18 with severe von Willebrand disease, a genetic bleeding disorder. The treatment was given with or without another factor product (ADVATE) for 12-18 months. The goal was to see how w…

This study tested a new medicine called BAX 930 in 52 people born with severe TTP, a rare blood-clotting disorder. The medicine replaces a missing enzyme to prevent or treat dangerous flare-ups. Participants received either BAX 930 or standard care for 6 months, then switched, fo…

This study tested a medication called rVWF (vonicog alfa) in 38 children and adults with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular treatment could reduce spontaneous bleeding episodes over 12 months. Participants received the drug for up t…